Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats

Mayako Soga, Fadia Kamal, Kenichi Watanabe, Meilei Ma, Suresh Palaniyandi, Paras Prakash, Punniyakoti Veeraveedu, Sayaka Mito, Megumi Kunisaki, Hitoshi Tachikawa, Makoto Kodama, Yoshifusa Aizawa

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Background: Daunorubicin is an anthracycline anti-tumor agent; anthracycline chemotherapy in cancer can cause severe cardiomyopathy leading to a frequently fatal congestive heart failure; the first-line treatment is diuretics and digoxin. Recently, angiotensin-converting enzyme inhibitors have been shown to be effective in the treatment of such toxicity. The purpose of this study was to investigate the effects of angiotensin II type-1 receptor antagonist (candesartan) in a rat model of daunorubicin-induced cardiomyopathy. Methods: Rats were treated with a cumulative dose of 9 mg/kg body weight daunorubicin (i.v.). 28 days later, after the development of cardiomyopathy, animals were randomly assigned to candesartan-treated (5 mg/kg/day, p.o.) or vehicle-treated groups; age-matched normal rats were used as the control group. Candesartan treatment was continued for 28 days. Hemodynamic and echocardiographic parameters were measured, cardiac protein and mRNA were analyzed, and histopathological analyses of myocardial fibrosis, cell size and apoptosis were conducted. Results: Following cardiomyopathy, left ventricular end diastolic pressure and left ventricular systolic dimension were significantly elevated; while % fractional shortening and Doppler E/A ratio were significantly reduced. Cardiomyopathic hearts showed significant increases in % fibrosis, % apoptosis, and myocyte diameter/body weight ratio; candesartan treatment reversed these changes. Fas-L protein overexpression in myopathic hearts was significantly suppressed by treatment with candesartan. Moreover, SERCA2 mRNA and protein expression were both down-regulated in myopathic hearts and restored to normal by candesartan treatment, significantly. Conclusions: Our findings suggest that candesartan treatment significantly improved the left ventricular function and reversed the myocardial pathological changes investigated in this model of daunorubicin-induced cardiomyopathy; suggesting its potentials in limiting daunorubicin cardiotoxicity.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalInternational Journal of Cardiology
Volume110
Issue number3
DOIs
StatePublished - Jun 28 2006

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats'. Together they form a unique fingerprint.

  • Cite this

    Soga, M., Kamal, F., Watanabe, K., Ma, M., Palaniyandi, S., Prakash, P., Veeraveedu, P., Mito, S., Kunisaki, M., Tachikawa, H., Kodama, M., & Aizawa, Y. (2006). Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. International Journal of Cardiology, 110(3), 378-385. https://doi.org/10.1016/j.ijcard.2005.08.061